Zydus Cadila gets USFDA approval for anti-viral drug Acyclovir

Sales of Acyclovir tablets in 2014 is estimated at $55.8 million: IMS

Pharmaceutical major Zydus Cadila has received final approval from United States Food & Drug Administration (USFDA) for marketing of anti-viral drug Acyclovir.

"Zydus Cadila has received the final approval from the USFDA to market Acyclovir tablets," the company said in a statement issued here today.

The approval has been granted for Acyclovir tablets in strengths of 400 mg and 800 mg, Zydus Cadila said.

According to IMS data, the sales of Acyclovir tablets in 2014 is estimated at $55.8 million.